Table 2.

Resistance phenotype, number of isolates, collection period, and antimicrobial activity of staphylococci for tedizolid and linezolid.

Microorganism/Study	Antimicrobial	Resistance Phenotype	Nº Isolates	Collection Period	Percent of Isolates (%) Inhibited at MIC (mg/L) of:
					≤0.12	0.25	0.5	1	2	4	8	>8
S. aureus
Sahm et al. [22]	Tedizolid		4499	2011–2012	10.8	55.2	33.9
	Linezolid					0.2	0.3	27.2	67.8	4.2	0.0	0.3
Zurenko et al. [23]	Tedizolid		7187	2008–2013	7.7	62.3	29.8	0.2	0.1	0.1
	Linezolid					0.1	0.3	21.6	72.8	4.9	0.0	0.2
Rodríguez-Avial et al. [24]	Tedizolid	LR	5	2010–2011			100
	Linezolid										60.0	40.0
Pfaller [25]	Tedizolid		4364	2014–2015	95.2	4.8
MRSA
Sahm et al. [22]	Tedizolid		1770	2011–2012	12.7	53.2	33.8	0.1	0.1	0.1
	Linezolid					0.2	0.3	30.8	65.7	2.7	0.0	0.3
Barber et al. [26]	Tedizolid	hVISA	120	Before 2016	20.8	45.9	31.6	1.7
		VISA	100		59.0	25.0	16.0
		DNS	75		30.7	50.6	18.7
		LR	7		28.6	28.5	0	42.9
Peñuelas et al. [27]	Tedizolid	MRSA	18	Before 2016	11.1	61.1	27.8
		MLRSA				11.1	11.1	72.2	5.6
	Linezolid	MRSA	18					38.9	61.1
		MLRSA									16.7	83.3
Pfaller et al. [25]	Tedizolid		1006	2014–2015	96.6	3.4
CoNS
Sahm et al. [22]	Tedizolid		537	2011–2012		51.4	39.1	8.6	0	0	0.7
Zurenko et al. [23]	Tedizolid		674	2008–2013	47.9	40.6	10.0	0.7	0.0	0.6	0.2
	Linezolid					0.9	23.2	61.2	12.6	1.2	0.1	0.8
Rodríguez-Avial et al. [24]	Tedizolid	LR	164	2010–2011	1.2	2.5	12.2	6.1	7.3	49.4	20.1	1.2
	Linezolid	LR									4.3	95.7
Pfaller et al. [25]	Tedizolid		729	2014–2015	98.6	1.2	0	0	0.1

Light grey: values under the susceptibility range. DNS: daptomycin-non-susceptible; LR: linezolid resistant; hVISA: heterogeneous vancomycin intermediate; VISA: vancomycin intermediate; MRSA: methicillin-resistant S. aureus, MLRSA: methicillin- and linezolid-resistant S. aureus.